Perspectum delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale.

Perspectum® was founded in partnership with the University of Oxford in 2012 after a ground-breaking study demonstrated the potential of T1 mapping to predict liver fibrosis. Perspectum’s flagship product, LiverMultiScan®, is a non-invasive diagnostic technology for evaluating liver diseases, using multiparametric MRI to non-invasively quantify liver tissue. Combining the information from multiple parametric maps provides a comprehensive analysis of liver tissue, which can be used to aid the diagnosis of liver disorders. This information is provided through software-as-a-service, in an easy-to-read report delivered directly to the physician or sponsor.

It’s second clinical use medical device, MRCP+™ is a non-invasive diagnostic tool that calculates quantitative 3D biliary system models. It enables the measurement of bile duct widths and automatic detection of regions of variation of duct widths. Recently Perspectum has launched Atlas®, a metabolic imaging suite redefining multi-organ assessment for clinical trials in diabetes and metabolic disease. It provides quantitative metrics of health and function across multiple organs from a single, non-contrast MR scan. This product is for investigational use only.

Perspectum and NCIMI

Perspectum is a proud partner of the NCIMI, with several projects focused on the development of AI-enabled tools that improve patient care. Most recently, Perspectum was awarded a grant under the NCIMI COVID Research Fund to support our recently launched COVERSCAN study, a landmark study of multi-organ phenotyping in patients recovering from COVID19.

For more information on Perspectum, please visit their website.